The estimated Net Worth of David S Snyder is at least 28.3 千$ dollars as of 12 March 2020. David Snyder owns over 18,248 units of Exicure Inc stock worth over 28,284$ and over the last 5 years David sold XCUR stock worth over 0$.
David has made over 1 trades of the Exicure Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently David bought 18,248 units of XCUR stock worth 25,547$ on 12 March 2020.
The largest trade David's ever made was buying 18,248 units of Exicure Inc stock on 12 March 2020 worth over 25,547$. On average, David trades about 18,248 units every 0 days since 2020. As of 12 March 2020 David still owns at least 18,248 units of Exicure Inc stock.
You can see the complete history of David Snyder stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE, IL, 60077.
Over the last 6 years, insiders at Exicure Inc have traded over 4,850,172$ worth of Exicure Inc stock and bought 7,217,940 units worth 10,705,021$ . The most active insiders traders include Timothy P Walbert、Co., Ltd. Dgp、Usa, Inc. Cbi. On average, Exicure Inc executives and independent directors trade stock every 90 days with the average trade being worth of 928,360$. The most recent stock trade was executed by Co., Ltd. Dgp on 29 February 2024, trading 3,400,000 units of XCUR stock currently worth 4,488,000$.
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Exicure Inc executives and other stock owners filed with the SEC include: